InvestorWire NewsRoom


Dyadic International Inc. (NASDAQ: DYAI) Featured in Virtual Coverage of Benzinga’s Global Small Cap Conference
December 7, 2020

Dyadic International Inc. (NASDAQ: DYAI) Featured in Virtual Coverage of Benzinga’s Global Small Cap Conference

Dyadic International Inc. (NASDAQ: DYAI) is a global biotechnology company that is applying its patented and proprietary C1 Gene Expression Platform Technology, to help animal and human pharmaceutical companies develop and manufacture biologic vaccines and drugs faster, with greater productivity and more affordably.  C1 is based on an industrially proven hyper-productive fungal cell line, which has been developed for over two decades, to provide an efficient and commercially cost-effective solution to produce large quantities of protein at flexible commercial scales. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals.

In addition to applying the C1 technology for use in the traditional animal and human health industries with top tier pharmaceutical and biotech companies, C1 is also being used to help develop SARS-CoV-2 vaccines and antibodies. Dyadic is currently in collaborations with the governments of Europe, Israel and the US to accelerate their SARS-CoV-2 vaccine development programs. In addition to the Frederick National Laboratory, there are 9 different academic, industry and government collaborations ongoing using Dyadic’s C1 SARS-CoV-2 vaccine candidates in their COVID-19 vaccine research and development programs. Up to 10 global animal trials are expected to be completed by the end of 2020 or early 2021. C1 has already successfully expressed a SARS-CoV-2 monoclonal antibody (mAb) in collaboration with IDBiologics, Inc., who licensed this mAb from the Vanderbilt Vaccine Center (“VVC”).

Dyadic’s President and CEO, Mark Emalfarb, will be presenting at the following sessions on Benzinga’s Global Small Cap Conference:

Company Presentation
Date: Tuesday, December 8, 2020
Time: 9:45 AM ET

Panel Discussion: COVID-19 and The Effect on BioTech
Date: Tuesday, December 8, 2020
Time: 2:45 PM ET

To learn more about the company, visit

For further details on Benzinga’s Global Small Cap Conference and other events, visit

About InvestorBrandNetwork’s Virtual Coverage

The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, covers dozens of investor conferences and online events as part of its ongoing service to the investment community. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN utilizes social media and syndicated articles to maximize the visibility of each featured session.

For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its many event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorBrandNetwork (IBN)
Los Angeles, California
310.299.1717 Office
[email protected]

Recent Articles

Release Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).